A compromise forged in crisis
The pharmaceutical industry's uneasy détente with the NHS hangs on a number: 14.5 per cent. That's the newly reduced rate at which drug companies must rebate revenues back to the health service, down from 22.5 per cent after months of brinkmanship that saw major players threaten to abandon UK expansion. Yet Sebnem Avsar Tuna, who runs Novo Nordisk's British operations, is already warning that this December compromise needs to stick—or the rollout of weight-loss treatments could stall before it properly begins.
Her intervention comes at a precarious moment for both parties. The NHS faces spiralling budget pressures whilst trying to address an obesity crisis affecting 64 per cent of English adults, according to government figures. Novo Nordisk, meanwhile, is defending its dominance in the lucrative weight-loss market from a position of surprising vulnerability.
The rebate reduction didn't emerge from goodwill. AstraZeneca and Merck had already scrapped UK investment plans by the time Health Secretary Wes Streeting entered negotiations last autumn. According to the Financial Times, he threatened to walk away entirely if pharma executives refused what he termed a "generous offer"—hardly the language of a sustainable partnership.
What makes Tuna's warning particularly pointed is the timing. Novo Nordisk's share price has collapsed from its €650bn valuation two years ago, when it briefly became Europe's most valuable company. The Danish firm announced 9,000 redundancies in September, followed by the departure of its chairman and six board members a month later. Eli Lilly's competing drug Mounjaro has steadily eroded Novo's market position, transforming what was essentially a monopoly into genuine competition.
This isn't a company speaking from strength. When Tuna describes the need for "predictability" in rebate rates, she's articulating concern from an organisation that's simultaneously fighting a market share battle and trying to secure access to national health systems that increasingly balk at the price tags attached to these treatments.
The volume game ahead
Dan Coatsworth, head of markets at AJ Bell, suggests the weight-loss drug sector could eventually shift to a volume model—lower margins, higher sales—if prices decline enough to make treatments accessible to broader populations. That calculation depends entirely on whether firms can secure stable terms with large institutional buyers like the NHS.
The commercial incentives are clear. Paul Major, an investment manager at Bellevue Asset Management, publicly disclosed in December that he'd sold his Novo holdings due to long-term concerns about the company's prospects. For a pharmaceutical giant that built its recent growth on weight-loss treatments, losing ground in major markets isn't an option.
Tuna positioned this competitive pressure as beneficial, arguing it "drives more research and more development, to get the best outcomes faster." Perhaps. But the evidence suggests it's primarily driving price competition in a market where the NHS has already restricted approval of Wegovy specifically because of cost concerns. NICE's limited endorsement of the drug wasn't based on efficacy questions—it was pure budget arithmetic.
The framing matters here. When Tuna describes obesity as an "unmet need" and insists Novo wants to be "part of the solution rather than being seen as the problem," she's casting a commercial expansion as public health altruism. The two aren't mutually exclusive, but neither are they identical. Novo Nordisk has invested in partnerships with Oxford University and established an AI research hub in King's Cross, genuine commitments to the UK market. Those investments also serve clear business objectives in a sector where regulatory approval and NHS adoption can make or break market access.
A structural conflict, not a settled dispute
The fundamental tension hasn't been resolved. The NHS operates under fixed budgets whilst facing effectively unlimited demand. Pharmaceutical companies answer to shareholders who expect growth and margins that reflect years of research investment. A weight-loss drug that works—genuinely works—represents both a public health breakthrough and a budgetary nightmare if deployed at population scale.
The current rebate rate of 14.5 per cent exists because the previous rate drove investment elsewhere. Yet there's little indication that NHS financial pressures will ease, or that future health secretaries won't face identical calculations about whether the UK can afford to be a primary market for expensive new therapies. Streeting's negotiating approach—publicly threatening to walk away—suggests the government understands its leverage even as it made concessions.
What happens when the next generation of weight-loss treatments emerges, potentially more effective and certainly more expensive? Or when evidence accumulates about long-term outcomes and optimal treatment durations? The rebate scheme will face renewed pressure from both directions: pharmaceutical companies seeking better terms, and NHS accountants tallying the cumulative costs of expanded access.
Tuna's warning about maintaining the current ceiling isn't unreasonable from Novo Nordisk's perspective. Stability in commercial terms does matter for long-term planning. But describing this as a fragile peace understates the case. This is a temporary ceasefire in a structural conflict between public healthcare financing and private pharmaceutical pricing—one that the weight-loss drug boom will test far more severely than anyone's yet acknowledged.
